Biotechnology
Medical
Cancer Prevention

Kura Oncology

$18.98
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-0.39%) As of 12:44 PM EDT today
-$0.07 (-0.39%) Today

Why Robinhood?

You can buy or sell Kura Oncology and other stocks, options, ETFs, and crypto commission-free!

About KURA

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. Read More The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.

Employees
43
Headquarters
San Diego, California
Founded
2014
Market Cap
727.12M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
543.43K
High Today
$19.29
Low Today
$18.79
Open Price
$19.03
Volume
112.49K
52 Week High
$22.00
52 Week Low
$10.20

Collections

Biotechnology
Medical
Cancer Prevention
Health
Research And Development
Biopharmaceutical
Pharmaceutical
2015 IPO

KURA Earnings

-$0.46
-$0.42
-$0.39
-$0.35
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 5, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.